|
|
Regorafenib(BAY73-4506)
Description of:Regorafenib(BAY73-4506)
BAY 73-4506 is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature...
More>>
|
|
|
|
Brivanib(BMS-540215)
Description of:Brivanib(BMS-540215)
Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
Theoret...
More>>
|
|
|
|
SU-5402
Description of:SU-5402
SU 5402 inhibits tyrosine phosphorylation of VEGFR2 and PDGFR in NIH 3T3 cells with IC50 values of 0.4 and 60.9 μM, r...
More>>
|
|
|
|
SU-6668(TSU-68)
Description of:SU-6668(TSU-68)
TSU-68 (SU6668)is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 µM, 8 nM and 1.2 &m...
More>>
|
|
|
|
AV-951(Tivozanib)
Description of:AV-951(Tivozanib)
AV-951 (Tivozanib) is a novel quinoline-urea derivative and now developed by AVEO. AV-951 also inhibits phosph...
More>>
|
|
|
|
Lenvatinib(E7080)
Description of:Lenvatinib(E7080)
Lenvatinib(E7080) has been evaluated in vitro (pre-clinical) for anti-cancer effects. E7080 suppresses lymph n...
More>>
|
|
|
|
Vatalanib Dihydrochloride
Description of:Vatalanib Dihydrochloride
Vatalanib is a potent, selective, orally active inhibitor of the VEGFR tyrosine kinases VEGFR-1 (Flt-1...
More>>
|
|
|
|
CP-673451
Description of:CP-673451
In a sponge angiogenesis model, CP-673451 inhibited 70% of PDGF-BB-stimulated angiogenesis at a dose of 3 mg/kg ...
More>>
|
|
|
|
KRN633
Description of:KRN633
KRN633 inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 µM and 4.33 µM, respective...
More>>
|
|
|
|
Cabozantinib
Description of:Cabozantinib
Cabozantinib was granted orphan-drug status by the FDA in January 2011.It is currently in a number of clinical tria...
More>>
|
|
Neuronal Signaling
BtK
Chinese
Deutsch
Espanol
Francais
Italiano
Portugues
Japanese
Korean
Arabic
Russian